Back to Search Start Over

Clinical factors influencing long-term survival in a real-life cohort of early stage non-small-cell lung cancer patients in Spain

Authors :
Torrente, Maria
Sousa, Pedro A.
Guerreiro, Gracinda R.
Franco, Fabio
Hernández, Roberto
Parejo, Consuelo
Sousa, Alexandre
Campo-Cañaveral, José Luis
Pimentão, João
Provencio, Mariano
DEE - Departamento de Engenharia Electrotécnica e de Computadores
CMA - Centro de Matemática e Aplicações
DM - Departamento de Matemática
Source :
Frontiers in Oncology. 13
Publication Year :
2023
Publisher :
Frontiers Media SA, 2023.

Abstract

Funding Information: This work was supported in part by Centro de Matematica e Aplicaçoes, UID (MAT/00297/2020), Portuguese Foundation of Science and Technology. Acknowledgments Publisher Copyright: Copyright © 2023 Torrente, Sousa, Guerreiro, Franco, Hernández, Parejo, Sousa, Campo-Cañaveral, Pimentão and Provencio. Background: Current prognosis in oncology is reduced to the tumour stage and performance status, leaving out many other factors that may impact the patient´s management. Prognostic stratification of early stage non-small-cell lung cancer (NSCLC) patients with poor prognosis after surgery is of considerable clinical relevance. The objective of this study was to identify clinical factors associated with long-term overall survival in a real-life cohort of patients with stage I-II NSCLC and develop a prognostic model that identifies features associated with poor prognosis and stratifies patients by risk. Methods: This is a cohort study including 505 patients, diagnosed with stage I-II NSCLC, who underwent curative surgical procedures at a tertiary hospital in Madrid, Spain. Results: Median OS (in months) was 63.7 (95% CI, 58.7-68.7) for the whole cohort, 62.4 in patients submitted to surgery and 65 in patients submitted to surgery and adjuvant treatment. The univariate analysis estimated that a female diagnosed with NSCLC has a 0.967 (95% CI 0.936 - 0.999) probability of survival one year after diagnosis and a 0.784 (95% CI 0.712 - 0.863) five years after diagnosis. For males, these probabilities drop to 0.904 (95% CI 0.875 - 0.934) and 0.613 (95% CI 0.566 - 0.665), respectively. Multivariable analysis shows that sex, age at diagnosis, type of treatment, ECOG-PS, and stage are statistically significant variables (p1) while adjuvant chemotherapy is a good prognostic variable (HR

Details

ISSN :
2234943X
Volume :
13
Database :
OpenAIRE
Journal :
Frontiers in Oncology
Accession number :
edsair.doi.dedup.....5d760bb0645af1b8ecece947c5d49e40
Full Text :
https://doi.org/10.3389/fonc.2023.1074337